You searched for rivaroxaban - Page 3 of 15 - MPR

Your search for rivaroxaban returned 143 results

Your search for rivaroxaban returned 143 results

Sort Results:

Relevant Recent
Drugs in the Pipeline

Phase 3 Study of Xarelto for Treatment and Secondary Prevention of Venous Blood Clots

Janssen Research & Development announced results of the EINSTEIN-PE study showing that Xarelto (rivaroxaban) was comparable to today's standard of care in treating patients with acute symptomatic pulmonary embolism (PE) and in preventing development of a secondary venous blood clot (known as venous thromboembolism or VTE).
News

Rivaroxaban Tied to Lower Brain Bleed Risk in A-Fib

A once daily oral dose of rivaroxaban (Xarelto) significantly lowers the risk of intracranial hemorrhage (ICH) in patients with atrial fibrillation (AF) at moderate to high risk of stroke.
News

Food Type, Timing Has No Clinically Relevant Impact on Rivaroxaban

Currently, the prescribing information recommends 20mg once daily with an evening meal for the AF indication, and 15mg twice daily with food for 21 days, followed by 20mg once daily with food for the remainder of treatment for the DVT/PE indications.
Clinical Charts

Anticoagulant Dosing Conversions

Recommended dosing conversions for anticoagulants such as warfarin, heparin, and dabigatran.
News

Xarelto Approved for Prevention of DVT

Janssen Pharmaceuticals announced FDA approval of Xarelto (rivaroxaban) tablets for the prevention of deep vein thrombosis (DVT) that may lead to a pulmonary embolism (PE) in people undergoing knee or hip replacement surgery.
American College of Cardiology 2013

Net Clinical Benefit of Rivaroxaban for Thrombosis Prevention in ACS Patients

After reports of having met the primary endpoints in the ATLAS-ACS TIMI-52 study, rivaroxaban 2.5mg and 5mg demonstrated a benefit over placebo in terms of cardiac mortality and bleeding risk as presented at ACC.13, the American College of Cardiology's 62nd Annual Scientific Session.